1 |
J. M. Siegfried, M. Farooqui, N. J. Rothenberger, S. Dacic, and L. P. Stabile, "Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer", Oncotarget, Vol. 8, pp. 24063-24076, 2017.
|
2 |
E. M. Haugsten, A. Wiedlocha, S. Olsnes, and J. Wesche, "Roles of fibroblast growth factor receptors in carcinogenesis", Mol. Cancer Res., Vol. 8, pp. 1439-1452, 2010.
DOI
|
3 |
Y. J. Shi, J. Y. Tsang, Y. B. Ni, S. K. Chan, K. F. Chan and G. M. Tse, "FGFR1 is an adverse outcome indicator for luminal A breast cancers", Oncotarget, Vol. 7, pp. 5063-5073, 2016.
DOI
|
4 |
N. Turner and R. Grose, "Fibroblast growth factor signalling: from development to cancer", Nat. Rev. Cancer, Vol. 10, pp. 116-129, 2010.
DOI
|
5 |
N. Brooks, E. Kilgour, and P. D. Smith, "Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer", Clin. Cancer Res., Vol. 18, pp. 1855-1862, 2012.
DOI
|
6 |
S. Lemieux and M. K. Hadden, "Targeting the fibroblast growth factor receptors for the treatment of cancer", Anti-Cancer Agents Med. Chem., Vol. 13, pp. 748-761, 2013.
DOI
|
7 |
R. Porta, R. Borea, A. Coelho, S. Khan, A. Araujo, P. Reclusa, T. Franchina, N. V. D. Steen, P. V. Dam, J. Ferri, R. Sirera, A. Naing, D. Hong, and C. Rolfo, "FGFR a promising druggable target in cancer: Molecular biology and new drugs", Crit. Rev. Oncol. Hematol., Vol. 113, pp. 256-267, 2017.
DOI
|
8 |
H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, and J. P. Spano, "Management of hypertension in angiogenesis inhibitor-treated patients", Ann. Oncol., Vol. 20, pp. 807-815, 2009.
DOI
|
9 |
S. Ricciardi, S. Tomao, and F. de Marinis, "Toxicity of targeted therapy in non-small-cell lung cancer management", Clin. Lung Cancer, Vol. 10, pp. 28-35, 2009.
DOI
|
10 |
B. Zhao, Y. Li, P. Xu, Y. Dai, C. Luo, Y. Sun, J. Ai, M. Geng, and W. Duan, "Discovery of substituted 1H-Pyrazolo[3,4-b]pyridine derivatives as potent and selective FGFR kinase inhibitors", ACS Med. Chem. Lett., Vol. 7, pp. 629-634, 2016.
DOI
|
11 |
M. Clark, R. D. Cramer III, and N. V. Opdenbosch, "Validation of the General Purpose Tripos 5.2 Force Field", J. Comput. Chem., Vol. 10, pp. 982-1012, 1989.
DOI
|
12 |
R. Kumar, B. Langstrom, and T. Darreh-Shori, "Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization", Sci. Rep., Vol. 6, p. 31247, 2016.
DOI
|
13 |
A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "A CoMFA study of glycogen synthase kinase 3 inhibitors", J. Chosun Natural Sci., Vol. 8, pp. 40-47, 2015.
DOI
|
14 |
A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "A CoMFA study of quinazoline-based anticancer agents", J. Chosun Natural Sci., Vol. 8, pp. 214-220, 2015.
DOI
|
15 |
A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "Comparative molecular field analysis of pyrrolopyrimidinesas LRRK2 kinase inhibitors", J. Chosun Natural Sci., Vol. 9, pp. 1-9, 2016.
DOI
|
16 |
P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "A CoMFA study of phenoxypyridine-based JNK3 inhibitors using various partial charge schemes", J. Chosun Natural Sci., Vol. 7, pp. 45-49, 2014.
DOI
|
17 |
M. Touat, E. Ileana, S. Postel-Vinay, F. Andre, and J. C. Soria, "Targeting FGFR signaling in cancer", Clin. Cancer Res., Vol. 21, pp. 2684-2694, 2015.
DOI
|
18 |
A. D. Luca, D. Frezzetti, M. Gallo, and N. Normanno, "FGFR-targeted therapeutics for the treatment of breast cancer", Expert Opin. Investig. Drugs, Vol. 26, pp. 303-311, 2017.
DOI
|
19 |
I. S. Babina and N. C. Turner, "Advances and challenges in targeting FGFR signalling in cancer", Nat. Rev. Cancer, Vol. 17, pp. 318-332, 2017.
DOI
|
20 |
K. H. Tiong, L. Y. Mah, and C.-O. Leong, "Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers", Apoptosis, Vol. 18, pp. 1447-1468, 2013.
DOI
|
21 |
E. M. Haugsten, A. Wiedlocha, S. Olsnes, and J. Wesche, "Roles of fibroblast growth factor receptors in carcinogenesis", Mol. Cancer Res., Vol. 8, pp. 1439-1452, 2010.
DOI
|
22 |
H. Greulich and P. M. Pollock, "Targeting mutant fibroblast growth factor receptors in cancer", Trends Mol. Med., Vol. 17, pp. 283-292, 2013.
|
23 |
H. K. Ho, A. H. Yeo, T. S. Kang, and B. T. Chua, "Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations", Drug Discov. Today, Vol. 9, pp. 51-62, 2014.
|